Trial Profile
An Open-label, Single-arm, Pilot Study to Evaluate the Effect of XmAb5871 on Disease Activity in Patients With IgG4-Related Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Obexelimab (Primary)
- Indications Immunological disorders
- Focus Therapeutic Use
- Sponsors Xencor
- 15 Nov 2023 Results of a PopPK model analysis from four clinical trials: a first-in-human, single-ascending dose study in healthy volunteers; 2) a multiple-ascending dose study in patients with RA; 3) an open-label study in patients with IgG4-RD; and 4) a PK and relative bioavailability study.
- 01 Aug 2023 Results presented in the Zenas Biopharma Media Release.
- 01 Aug 2023 According to a Zenas Biopharma media release, results from this trial were published in the Lancet Rheumatology.